Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Biocept Inc

Current price
0.046 USD -0.012 USD (-20.83%)
Last closed 0.045 USD
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 1 142 060 USD
Yield for 12 month -93.95 %
21.11.2021 - 28.11.2021

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. Address: 9955 Mesa Rim Road, San Diego, CA, United States, 92121


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

+25 858 000 USD

Last Year

+61 249 000 USD

Current Quarter

+589 000 USD

Last Quarter

-10 285 000 USD

Current Year

-2 582 000 USD

Last Year

+23 485 000 USD

Current Quarter

-1 961 000 USD

Last Quarter

-14 592 000 USD

Key Figures BIOC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -31 328 000 USD
Operating Margin TTM -1038.03 %
PE Ratio
Return On Assets TTM -51.65 %
PEG Ratio -0.04
Return On Equity TTM -186.94 %
Wall Street Target Price 4 USD
Revenue TTM 1 357 000 USD
Book Value 0.12 USD
Revenue Per Share TTM 1.97 USD
Dividend Share
Quarterly Revenue Growth YOY -89.9 %
Dividend Yield
Gross Profit TTM -2 582 000 USD
Earnings Share -48.17 USD
Diluted Eps TTM -48.17 USD
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BIOC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BIOC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:30
Payout Ratio
Last Split Date 17.05.2023
Dividend Date 08.09.2020

Stock Valuation BIOC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.0893
Price Sales TTM 0.1974
Enterprise Value EBITDA -0.3364
Price Book MRQ 0.3719

Financials BIOC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BIOC

For 52 weeks

0.045 USD 23.85 USD
50 Day MA 0.95 USD
Shares Short Prior Month 610 577
200 Day MA 5.33 USD
Short Ratio 0.05
Shares Short 29 728
Short Percent 0.57 %